Thermo Fisher Scientific and Daiichi Sankyo continue to collaborate, this time on the co-development of a companion diagnostic for patients with non-small cell lung cancer using Thermo Fisher's Oncomine Dx Target Test designed to evaluate multiple biomarkers associated with cancer and identify patients who are eligible for multiple targeted therapies using a single sample. Results are available within days.

The CDx will be designed to identify NSCLC patients with human epidermal growth factor receptor 2 mutations who may be eligible for Enhertu, a HER2 directed antibody drug conjugate currently in global phase 2 development for HER2 mutated or HER2 overexpressing NSCLC. Thermo Fisher will retain rights to commercialize the test globally and will file for the applicable regulatory approvals.

“This agreement underscores our continued commitment to working with global pharmaceutical partners to efficiently identify more patients who may benefit from the latest targeted therapies in their drug pipelines“

Garret Hampton, president of clinical next-generation sequencing and oncology at Thermo Fisher Scientific, said: "Our latest partnership with Daiichi Sankyo is focused on helping to solve an unmet medical need for a growing number of patients with HER2-mutated non-small cell lung cancer. This agreement underscores our continued commitment to working with global pharmaceutical partners to efficiently identify more patients who may benefit from the latest targeted therapies in their drug pipelines."